Roche's Divarasib Shows Strong Results in Advanced Lung Cancer Trial

Roche has reported positive outcomes from its Phase III Krascendo 1 study for divarasib, an investigational KRAS G12C inhibitor. The drug demonstrated significant improvements in progression-free and overall survival for patients with previously treated non-small cell lung cancer, outperforming existing therapies. No new safety concerns were identified, suggesting a potential new treatment option.